MLMiriam N. Lango

Miriam N. Lango

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Miriam N. Lango has a total of 209 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EHR ‐Integrated Synoptic Operative Reporting for Head and Neck Oncologic Surgery

    by Miriam N. Lango, Avery Sinnathamby, Marc‐Elie Nader, Paul W. Gidley, Karen Y. Choi, Mark Zafereo, Carly E. A. Barbon, Kristen B. Pytynia, Anastasios Maniakas, Amy Hessel, et al.

    Objective: To describe the development and implementation of electronic health record (EHR)‐integrated synoptic operative templates for head and neck oncologic surgery and to evaluate documentation adherence and performance. Methods: Single‐institution retrospective quality improvement study of extirpative oncologic resections (mucosal, cutaneous, thyroid, salivary gland, and skull base) performed at a tertiary academic cancer center from January 2025 through April 2026. Tumor‐specific adaptive synoptic templates were developed through literature review, professional society guidance, and subspecialty consensus and integrated into the EHR. Adherence was defined as synoptic template use for eligible cases; performance was defined as the proportion of cases with complete and internally consistent synoptic data, with an acceptable rate set at 90% or higher. The first 253 consecutive cases with synoptic documentation underwent detailed performance review. Results: Departmental adherence increased from 49% to 69%–78% over the final 6 months and varied among surgeons (range, 7%–100%). Surgeons who personally completed operative reports adhered more often than those delegating to trainees (85% vs. 56%; p < 0.001), as did high‐volume surgeons (85% vs. 56%; p < 0.001). Among 253 reviewed cases, 239 (94.5%) met the completeness and consistency target. Missing data exceeded inaccuracies (12 vs. two cases). Performance failures were more frequent with the thyroid template than with all other templates combined (10.8% vs. 1.8%; p < 0.001). Conclusion: EHR‐integrated synoptic operative templates for head and neck oncologic surgery demonstrate acceptable documentation performance but variable uptake. The underlying structured data framework may support multicenter standardization, registry‐based outcomes research, and AI‐enabled surgical documentation. Level of Evidence: Not applicable.

  • A Standardized Algorithm's Impact on Primary Detection in Head and Neck Carcinoma of Unknown Primary

    by Thomas G. Townes, Julian Martinez, Neil D. Gross, Guojun Li, Ryan Goepfert, Jeffrey Myers, Andrew G. Sikora, Karen Choi, Katherine A. Hutcheson, Wenye Song, et al.

    Objective(s): National guidelines for HPV‐associated head and neck squamous cell carcinoma of unknown primary (HNSCCUP) were adapted into a standardized institutional diagnostic algorithm. This study evaluated the impact of algorithm implementation on primary site detection, treatment selection, and oncologic outcomes. Study Design: Retrospective implementation study. Setting: Single tertiary‐care cancer center. Methods: We reviewed patients with clinically occult, PET/CT nonlocalizing HPV‐associated HNSCCUP treated before (2014‐2021) and after (2022‐2023) implementation of the algorithm. Results: Among 139 patients, those treated after algorithm implementation (n = 33) were more likely to undergo robotic ipsilateral lingual ± palatine tonsillectomy rather than bilateral palatine tonsillectomy, resulting in higher mucosal detection rates (88% vs 59%, P = .003). Postimplementation patients were more likely to receive primary surgical rather than nonsurgical treatment (54% vs 20%, P < .001) and unilateral radiotherapy without elective contralateral nodal irradiation (78% vs 43.5%, P = .002). Algorithm implementation was associated with a fourfold increase in the odds of primary site detection (OR 4.1, 95% CI 1.3‐13.0, P = .018); however, detection rates also increased in HNSCCUPs not managed with robotic surgery, from 57% to 87% ( P = .04). After implementation, 21.2% of patients received surgery alone compared with 5.7% prior, while postoperative chemoradiation was used in 9.1% versus 3.8%, respectively. No locoregional failures have occurred since implementation. Conclusion: Implementation of a standardized diagnostic algorithm for HPV‐associated HNSCCUP significantly improved primary site detection and altered treatment without compromising disease control. Improvements in detection were not fully explained by the use of robotic surgery. Potential functional benefits warrant further study. Level of Evidence: 4.


  • Open Access

    Deceptive Thyroid Pathologies: Anaplastic Thyroid Carcinoma Mimics and Clinical Implications

    by David Z. Allen, S. Mohsen Hosseini, Mark Zafereo, Miriam Lango, Elizabeth Gardner Grubbs, Priyanka Iyer, Shreyaskumar R. Patel, Vinod Ravi, Naifa Lamki Busaidy, Rui Jennifer Wang, et al.

    Background: Beyond follicular‐derived thyroid carcinomas, lymphomas, and metastatic disease, there are rare pathologies of the thyroid gland that represent a challenge. We report patients with unusual malignancies that mimic similar aggressive cancers. Methods: Retrospective case series. Results: Eight patients with aggressive thyroid tumors presented with clinical and radiographic features concerning for anaplastic thyroid cancer (ATC). Three patients presumed to be diagnosed with Adamantinoma‐like Ewing sarcoma (ALES), each harboring an EWSR1‐FLI1 rearrangement. One patient with an enlarging neck mass was found to have osteoid‐producing osteosarcoma. Another patient with a bulky neck mass and metastases demonstrated neolumen and ERG/CD31 positivity, confirming thyroid angiosarcoma. A separate patient was diagnosed with a high‐grade sarcoma harboring a PRMT8‐NTRK fusion, representing the first reported case. Two patients had mucoepidermoid carcinoma (MEC) variants—one classic MEC and one sclerosing MEC with eosinophilia (SMECE). Conclusions: Multiple rare thyroid malignancies may present indistinguishably from ATC, emphasizing the need for meticulous histopathologic and molecular evaluation.


  • Open Access

    Designing an Electronic Patient-Reported Outcomes Information Infrastructure Supported by the RE-AIM Implementation Framework

    by Amy C. Moreno, Angela Peek, Toshiko S. Shein, Kevin R. Shook, Sara M. Ali, Laia Humbert-Vidan, Aileen Chen, Miriam Lango, Anna Lee, Michael Spiotto, et al.

    Objective: Patient-reported outcomes (PROs) contain valuable information that can be leveraged by providers to perform timely interventions and improve quality of life and survival. However, the implementation of electronic PROs (ePROs) remains a challenge from technical and evaluation perspectives. Our objective was to construct a robust electronic health record (EHR)-integrated ePRO information infrastructure founded on RE-AIM (reach-effectiveness-adoption-implementation-maintenance) principles. Materials and Methods: We used Epic Systems as our EHR platform to build the MD Anderson Symptom Index Head and Neck Module (MDASI-HN) for release to all patients undergoing evaluation and/or treatment in our HN Radiation Oncology clinics. RE-AIM metrics were established and used to design patient, provider, and implementing facilitator information tools. Results: From January 2021 to July 2024, our ePRO program has collected 13,156 patient-submitted ePROs on 3,497 unique HN patients, with a 12-month sustained ePRO compliance rate of 82%. We also propose a dynamic 2-cycle implementation model. This model can be used to continuously (re)define, build, and adapt ePRO information tools for patients, providers, and program facilitators. Discussion: Our ePRO framework has several benefits, including integrated clinical data for enhanced decision-making, potential scalability, and use of a common EHR system. Formative (ie, mid-phase) evaluations were essential to our program, allowing for timely optimization of ePRO compliance, ePRO usage by clinical staff, and secondary use of high-quality ePRO data. Conclusion: In this article, we provide a valuable roadmap toward developing a comprehensive, EHR-based ePRO information infrastructure simultaneously optimized for clinical utility, informatics operations, and implementation evaluation founded on RE-AIM principles.


  • Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer

    by Barbara Burtness, Yael Flamand, Harry Quon, Gregory S. Weinstein, Ranee Mehra, Joaquin J. Garcia, Seungwon Kim, Bert W. O'Malley, Enver Ozer, Chukwuemeka Ikpeazu, et al.

    This phase II trial of transoral surgery (TOS) with deintensified postoperative management in human papillomavirus (HPV)–associated oropharynx cancer (OPC) enrolled patients with resectable cT1-2 stage III/IV American Joint Committee on Cancer (AJCC) seventh edition p16+ OPC without matted neck nodes. Those with clear margins, 0-1 + nodes (LN), and no extranodal extension (ENE) were observed (arm A); those with clear margins, 2-4 + LN, or ENE ≤1 mm were randomly assigned to 50 Gy (arm B) or 60 Gy (arm C); and those with involved margins, >4 + LN, or >1 mm ENE received weekly cisplatin and 60-66 Gy (arm D). Among 359 evaluable patients, the 54-month progression-free (PFS) and overall survival (OS) were 90.6% (90% CI, 87.2% to 93.1%) and 95.3% (93.0% to 96.9%), respectively. The 54-month PFS by arm was A 93.2% (79.6% to 97.8%; all four recurrences among N1 patients), B 94.9% (89.7% to 97.5%), C 90.2% (82.7% to 94.6%), and D 85.5% (77.5% to 90.8%). The 54-month OS by arm was A 97.1% (85.7% to 99.4%), B 97.9% (93.5% to 99.3%), C 95.1% (90.1% to 97.6%), and D 92.5% (86.9% to 95.7%). PFS or OS did not differ by primary site or smoking history. TOS and neck dissection with deintensified postoperative management results in outstanding 54-month PFS and OS. Among patients with favorable pathologic characteristics, those with N1 disease are at risk of late recurrence without radiation.


  • Open Access

    Supplementary Table S13 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade

    by Xianli Jiang, Nils-Petter Rudqvist, Bo Jiang, Shengbin Ye, Shan He, Qingnan Liang, Jinzhuang Dou, Michelle D. Williams, Joe Dan Dunn, Jason M. Johnson, et al.

    Sample-level cell counts of CD8 clusters

  • Open Access

    Supplementary Table S19 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade

    by Xianli Jiang, Nils-Petter Rudqvist, Bo Jiang, Shengbin Ye, Shan He, Qingnan Liang, Jinzhuang Dou, Michelle D. Williams, Joe Dan Dunn, Jason M. Johnson, et al.

    Statistical test for association of lymphocyte cluster proportion with progression

  • Open Access

    Supplementary Figures S1-S18 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade

    by Xianli Jiang, Nils-Petter Rudqvist, Bo Jiang, Shengbin Ye, Shan He, Qingnan Liang, Jinzhuang Dou, Michelle D. Williams, Joe Dan Dunn, Jason M. Johnson, et al.

    Fig. S1. Patient disposition and characteristics. Fig. S2. Timing of OI biopsy collection did not correlate with response. Fig. S3. Major cell types identified in the tumor immune microenvironment. Fig. S4. CD4+ T cells identified in the tumor immune microenvironment. Fig. S5. Effector Treg cells in the HPV-positive OPC TIME highly express activation markers. Fig. S6. Treatment-induced changes in Treg proportions and clonotype frequencies. Fig. S7. CD8+ T cells in MHRs have different transcriptional programs vs those in nMHRs. Fig. S8. CD8+ T cells identified in the tumor immune microenvironment. Fig. S9. T cell clusters did not vary by anatomic site. Fig. S10. TRM CD8+ T cells had high expression of tumor-reactive, cytotoxic and checkpoint genes. Fig. S11. Fluorescent imaging of antigen-experienced, memory CD8+ T cells in baseline tumors. Fig. S12. Clonality of CD4+ T-cell TCR repertoire. Fig. S13. CD8+ T-cell TCR repertoire clonality and dynamics. Fig. S14. Phenotypes of treatment-altered CD8 clonotypes varied by response. Fig. S15. Predominant phenotypes of treatment-responsive CD8+ T-cell clonotypes. Fig. S16. Identification of HPV-specific TCRs. Fig. S17. NK cells that express Fc gamma receptor IIIa (CD16) are more activated than those that do not. Fig. S18. Increase in proportion of Effector1(IFNG+) cells associated with reduction in tumor viability.

  • Open Access

    Supplementary Tables S1-S6 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade

    by Xianli Jiang, Nils-Petter Rudqvist, Bo Jiang, Shengbin Ye, Shan He, Qingnan Liang, Jinzhuang Dou, Michelle D. Williams, Joe Dan Dunn, Jason M. Johnson, et al.

    Table S1. Patient and tumor characteristics. Table S2. Representativeness of study participants. Table S3. Clinical and histopathologic characteristics of individual patients. Table S4. Treatment related adverse events that occurred after first dose. Table S5. Adverse events related to immune checkpoint blockade. Table S6. Serious adverse events.

  • Open Access

    Supplementary Table S20 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade

    by Xianli Jiang, Nils-Petter Rudqvist, Bo Jiang, Shengbin Ye, Shan He, Qingnan Liang, Jinzhuang Dou, Michelle D. Williams, Joe Dan Dunn, Jason M. Johnson, et al.

    Clinical and single-cell features used in multivariable regression models